{"entity":{"id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","aka":[],"tldr":"A phase 1/2 trial in triple-negative breast cancer, run by CoRegen, Inc., not yet recruiting.","summary":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies is a phase 1/2, interventional study registered as NCT07730125 by CoRegen, Inc., with a registry enrolment figure of 67 participants, started 2026-11 and due to reach its primary completion in 2029-06. Interventions recorded: CRG-150. Conditions listed: HR-positive, HER2-negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Prostate Cancer. Triple-negative eligibility wording from the registry: \"TNBC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07730125","url":"https://clinicaltrials.gov/study/NCT07730125"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07730125","phase":"1/2","setting":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","sponsor":"CoRegen, Inc.","enrolled":67,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07730125/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}